VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2020 | NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer

Giampaolo Bianchini, MD, of IRCCS San Raffaele Hospital, Milan, Italy, discusses data coming from the NeoTRIPaPDL1 trial (NCT02620280) – a randomized Phase III study evaluating neoadjuvant atezolizumab with carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer. The data presented at ESMO 2020 looked at the role of tumour infiltrating lymphocytes (TILs) and PD-L1 expression in samples collected at baseline, Day 1 of cycle 2 or at surgery. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter